加载中
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
前收盘价
US$2.00
+US$0.01 · +0.50%
盘中时间采用ET。市场数据可能有所延迟。
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$2.00
52周区间
当前US$2.00
盘中时间采用ET。市场数据可能有所延迟。
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$2.00
52周区间
当前US$2.00
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3090.9万 USD | 2260.2万 USD | 3415.5万 USD | 1922.8万 USD | 131.9万 USD |
| 销货成本 | 333.2万 USD | — | — | — | — |
| 毛利 | 2757.7万 USD | 2260.2万 USD | 3415.5万 USD | 1922.8万 USD | 131.9万 USD |
| 研究与开发 | 8546.6万 USD | 9452.8万 USD | 1.1亿 USD | 1.06亿 USD | 8032.5万 USD |
| 销售、一般及管理费用 | 2755万 USD | 2835.9万 USD | 3237.2万 USD | 3074.7万 USD | 2172.8万 USD |
| 营业费用 | 1.1亿 USD | 1.25亿 USD | 1.42亿 USD | 1.36亿 USD | 1.02亿 USD |
| 利息收入 | 874.5万 USD | 1190万 USD | 1087.5万 USD | 567.5万 USD | 5.9万 USD |
| 利息支出 | — | — | — | — | 190.6万 USD |
| 折旧和摊销 | 333.2万 USD | 312万 USD | 345.1万 USD | 332.1万 USD | 322.7万 USD |
| 营业利润 | −8210.7万 USD | −1.03亿 USD | −1.08亿 USD | −1.17亿 USD | −1.01亿 USD |
| 净利润 | −7428.3万 USD | −8662万 USD | −9842.6万 USD | −1.09亿 USD | −1.01亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.25
上涨空间 112.50%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI642.12万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF245.85万0.00%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 ETFIWM182.32万0.00%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Russell 2000 ETFVTWO120.15万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO67.9万0.00%139.17亿 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB48.43万0.00%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 Growth ETFVTWG22.85万0.01%17亿 USD0.06%US$260.49+0.91%
iShares Micro-Cap ETFIWC22.72万0.02%13.17亿 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 Growth ETFVTWGiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
